Table 4. Univariate analysis of progression-free survival and overall survival in patients with wild-type EGFR.
| Parameter | No. of patients | Progression-free survival | Overall survival | ||
|---|---|---|---|---|---|
| Mean survival time(months ±SE) | P value | Mean survival time(months ±SE | P value | ||
| Age | |||||
| <64 | 48 | 7.58±0.73 | 0.973 | 18.16±1.34 | 0.751 |
| ≥64 | 37 | 7.83±0.63 | 18.72±1.76 | ||
| Sex | |||||
| Male | 38 | 6.65±0.67 | 0.038 | 15.46±1.44 | 0.009 |
| Female | 47 | 8.62±0.65 | 20.60±1.42 | ||
| Smoker | |||||
| + | 55 | 7.54±0.64 | 0.606 | 19.30±1.61 | 0.543 |
| - | 30 | 8.21±0.76 | 17.92±1.39 | ||
| ECOG performance status | |||||
| 0/1 | 49 | 8.40±0.69 | 0.147 | 19.20±1.37 | 0.497 |
| 2/3/4 | 36 | 6.94±0.66 | 17.32±1.72 | ||
| Serum CEA level | |||||
| Normal(≤5) | 60 | 7.74±0.51 | 0.948 | 18.17±1.18 | 0.711 |
| High(>5) | 25 | 7.69±1.08 | 18.90±2.31 | ||
| Serum LDH level | |||||
| High | 14 | 5.54±0.95 | 0.007 | 18.34±2.02 | 0.048 |
| Normal | 71 | 8.20±0.54 | 13.78±2.41 | ||
| TLGT | |||||
| <104.65 | 51 | 8.55±0.70 | 0.026 | 20.27±1.54 | 0.024 |
| ≥104.65 | 34 | 6.61±0.59 | 15.73±1.35 | ||
| TLGWBR | |||||
| <259.85 | 40 | 9.74±0.77 | 0.000 | 22.09±1.57 | 0.001 |
| ≥259.85 | 45 | 6.02±0.51 | 15.71±1.26 | ||
Abbreviations: ECOG: Eastern Cooperative Oncology Group; TLGT: primary tumor total lesion glycolysis (TLG); TLGWBR: whole-body total TLG determined using the Response Evaluation Criteria In Solid Tumors 1.1 criteria.